Overview

This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.

Eligibility

Inclusion Criteria:

• Trial participants aged 18 years or older at baseline, with no restrictions on gender.
• Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.

Exclusion Criteria:

• Known history of allergic reaction to Stapokibart Injection.
• Trial participants currently or plan participating in any interventional clinical trial.
• Trial participants with hematologic malignancies.
• Women with pregnant.
• Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.